Among vaccinated people, the risk of having a severe form is highly related to age, taking immunosuppressants, oral corticosteroids or the presence of comorbidities. This observation is not new, but it is the result ofan extensive study carried out by the Epi-Phare structurewhich combines Health Insurance (Cnam) and the Medicines Agency (ANSM), published this Friday, February 11, 2022.
This large-scale study was carried out on all people with a complete vaccination schedule – two doses or one dose and one infection – as of July 31, 2021, i.e. 28 million people in total.
Of this entire vaccinated population, 5,345 people were hospitalized and 996 died during this follow-up.
Geographical location has an impact on the risk of severe forms
According to the study, the risks of severe forms are largely related to age. For example, people aged 85 to 89 are at risk four times higher to be hospitalized, and 38 times higher to die than people aged 45 to 49.
But, more surprisingly, the geographical location would have an impact on the serious forms, even in people with a complete vaccination schedule: the inhabitants of the most disadvantaged municipalities have a risk of hospitalization 1.3 times higher.
The more comorbidities, the greater the risk
Also according to the study, only 10% of hospitalized vaccinated patients and 2% of deceased vaccinated had no comorbidity. That is twice less than in the total unvaccinated population of the first two waves. And among hospitalized vaccinees, 12% of patients had one comorbidity, 16% had two, 18% had three, 16% then had four, and 27% had five or more.
“These results confirm the very low risk of hospitalization in vaccinated“, welcomes Mahmoud Zureik, director of the Epi-Phare structure. “They also suggest the importance of vaccination combined with complementary preventive measures to further avoid the risk of severe forms of Covid-19 in vaccinated people, in particular the elderly and immunocompromised populations.“, he concludes.
Source :
Characteristics associated with the residual risk of a severe form of COVID-19 after a complete vaccination schedule in France, Epi-Phare, 11 February 2022.
Read also:
- Variant Omicron: symptoms, incubation period, contagion
- Paxlovid (ritanir): Pfizer’s anti-Covid treatment in 5 questions
- Covid-19 and cancer: RNA vaccines do not present additional risks for patients
